Growth hormone (HGH) for women 40 and over

In clear terms

Growth hormone (GH / HGH) is added alongside the normal stimulation drugs in some IVF cycles, usually for older women or poor responders, on the idea that it helps the follicle mature a better egg. Individual trials have been small and often could not reach statistical significance on their own - which is exactly why a meta-analysis, pooling them, is useful.

This 2023 meta-analysis did something we care about: it isolated women aged 40 and over. In that group, adding GH was associated with clinical pregnancy odds roughly doubled (odds ratio 2.2, 95% confidence interval 1.34 to 3.61) and live birth odds about four times higher (odds ratio 4.12, 95% confidence interval 1.82 to 9.32). Both were statistically significant.

When one heterogeneity-driving trial was removed, the clinical pregnancy result actually got cleaner and held up (odds ratio 2.77, 95% confidence interval 1.75 to 4.39, with zero measured heterogeneity) - so the effect is not resting on a single odd study.

The honest caveat: the individual trials are small, a few had very few events, and most of the original papers sit behind paywalls, so the per-study numbers here come from the meta-analysis's own extracted data rather than from reading each original in full. An odds ratio is a ratio, not a plain percentage, so a 4x live-birth odds does not mean 4x the live-birth rate - it is a large relative lift on a low older-women baseline.

What changed: every outcome, with its size

Outcome	IVF without GH	IVF + growth hormone	Difference (and how big)	Significant?
Clinical pregnancy (women 40+)	pooled comparator	GH cotreatment	odds ratio 2.2 (95% CI 1.34-3.61) - roughly double the odds of a clinical pregnancy; significant (large)	Yes
Live birth (women 40+)	pooled comparator	GH cotreatment	odds ratio 4.12 (95% CI 1.82-9.32) - about four times the odds of a live birth, though on a low older-women baseline and from small trials; significant (huge)	Yes
Clinical pregnancy (sensitivity, one trial removed)	pooled comparator	GH cotreatment	odds ratio 2.77 (95% CI 1.75-4.39), heterogeneity I-squared 0% - the effect got cleaner, not weaker, when the outlier trial was dropped (large)	Yes
Euploid blastocyst rate (companion study, advanced maternal age)	about 20%	about 35%	in the linked AMA study (PMC13041122), GH was associated with the euploid rate rising from roughly 20% to 35% - the plausible mechanism for the live-birth gain here (large)	Yes

The trade-off, weighed

The protocol: exact dosage, so you can copy it

Always confirm any dose and protocol with your own clinic. This is what the study did, not a prescription.

The euploidy read

Who this helps

Women 40 and over doing IVF - the exact group this meta-analysis isolated, and where the signal is strongest.
Poor ovarian responders / diminished reserve, the usual population these GH trials recruited.
Anyone weighing GH as an add-on who wants the pooled evidence rather than one small trial's result.

Who this does NOT apply to (were not eligible)

Younger women with normal response - the benefit was specifically modelled in the 40+ / poor-responder group, not the general IVF population.
Anyone expecting certainty: these are small trials with wide confidence intervals; the meta improves confidence but does not settle it.
This is about pregnancy/live-birth odds, not a guarantee of more eggs or embryos in a given cycle.

Does it apply to older women?

This is unusually age-relevant: the meta-analysis deliberately restricted to women 40 and over, which is exactly our community. The live-birth odds ratio of 4.12 is a 40+ result, not a general-population one. Single-year cut-offs (41 vs 43) are not separately powered, so we read it as strong 40+ evidence.

The study

Design: Systematic review and meta-analysis, Included randomised and some non-randomised controlled trials, Subgroup: women 40+
Size: None participants
Embryos PGT-tested? Mixed / not stated across trials
Protocol / dosing: Growth hormone added to standard gonadotropin stimulation; dose/duration varied across the included trials (a known source of noise).
Location / year: International (pooled), 2023
Evidence level: Meta-analysis (higher up the evidence hierarchy) but built on SMALL individual trials with wide intervals - promising, not definitive. Best-available pooled older-women evidence for GH.

Caveats & safety

Small included trials, some with very few events (one had double-zero events and was handled separately). Most originals are paywalled, so per-study percentages here come from the meta's extracted data, not each original's full text (the paywall is the reason we could not enrich every included trial as its own entry). Odds ratios overstate the apparent effect versus plain rate differences on a low baseline.

Adverse events: Not a focus of the pooled analysis; GH is generally well tolerated in these short IVF courses, but safety was not the endpoint.

Michelle's thoughts

This is the flip side of what I wrote on my HGH page. There I flagged that so many of these GH studies 'could not get to statistical significance' on their own, and that the Cochrane review landed on 'uncertain' - all true, the individual trials are small and messy. But that is precisely what a meta-analysis is for, and when you pool them and isolate the over-40s, the signal is hard to ignore: clinical pregnancy doubled, live birth four times the odds. I don't read that as 'HGH is proven' - I read it as 'there is a real, large older-women signal here that the underpowered single trials kept missing.' It also fits my hunch about mechanism: the linked euploid-rate study suggests GH is lifting embryo quality, which is the whole game for us. I'm still chasing the IGF-1 / metformin angle because I suspect how you support GH's downstream signalling may be why it works for some of us and not others. Bottom line: worth raising with a clinic if you're 40+, eyes open that the trials are small.

The size, in relative terms

Source

https://pmc.ncbi.nlm.nih.gov/articles/PMC10083671/

Michelle's own HGH research notes: